PharmaResearch Products, the South Korean manufacturer of Rejuran (polynucleotide skin booster), has acquired a cosmetic group, signaling aggressive portfolio consolidation in the biostimulator and skin-rejuvenation space. The deal expands PharmaResearch's footprint beyond its flagship PN platform into adjacent aesthetic categories.
Business & M&A
Rejuran Maker PharmaResearch Acquires Cosmetic Group
South Korean injectable manufacturer expands portfolio through acquisition.
Get the free Inside MedSpa brief by email
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
Rejuran acquisition signals PharmaResearch's push into adjacent aesthetic categories.
Rejuran has gained traction in Asia-Pacific and emerging European markets as a lower-cost alternative to PLLA and CaHA biostimulators, targeting the preventive and maintenance-treatment segment. The acquisition likely aims to cross-sell Rejuran into the acquired group's distribution network and clinical practice base, accelerating market penetration. For U.S. practices, Rejuran remains unapproved by the FDA, though off-label use and medical tourism continue to drive awareness among patients seeking alternatives to established biostimulators.
Source: original report ↗
Frequently asked questions
Is Rejuran approved by the FDA in the United States?
No, Rejuran is not FDA-approved for use in the U.S. However, some practices use it off-label, and patients also seek it through medical tourism, particularly in Asia-Pacific markets where it is established and approved.
What is Rejuran and how does it work as a skin treatment?
Rejuran is a polynucleotide (PN) skin booster manufactured by South Korean company PharmaResearch Products. It functions as a biostimulator that stimulates collagen production for skin rejuvenation and is positioned as a lower-cost alternative to PLLA and calcium hydroxyapatite (CaHA) biostimulators.
How much does Rejuran cost compared to other biostimulators?
Rejuran is marketed as a lower-cost alternative to established biostimulators like PLLA and CaHA, though specific pricing varies by market and provider. It targets the preventive and maintenance-treatment segment where cost-conscious patients seek value.
Why did PharmaResearch acquire a cosmetic group?
The acquisition allows PharmaResearch to expand beyond its flagship Rejuran platform into adjacent aesthetic categories and cross-sell Rejuran through the acquired group's existing distribution network and clinical practices, accelerating market penetration.
What markets is Rejuran currently available in?
Rejuran has gained significant traction in Asia-Pacific and emerging European markets. It remains unapproved in the U.S., though awareness is growing among patients interested in biostimulator alternatives through medical tourism.
Business information, not medical or legal advice. Verify product status at FDA.gov.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.